Sanofi will gain exclusive rights to commercialize the lead-212-based radiopharmaceutical AlphaMedix in somatostatin-expressing neuroendocrine cancers.
Precision Medicine Online’s Post
More Relevant Posts
-
The company said the single-arm multicenter Phase II trial may support accelerated approval for the RP-A501 gene therapy in the US.
Rocket Pharma Completes Enrollment of Pivotal Trial Assessing Danon Disease Gene Therapy
precisionmedicineonline.com
-
Patients on therapies recommended by an MTB had better progression-free survival and overall response rates than those on standard-of-care therapy.
ROME Trial Shows Benefit of Tumor-Agnostic Targeted Therapy Guided by a Molecular Tumor Board
precisionmedicineonline.com
-
Besides making diagnoses, the newest center in the NIH Undiagnosed Diseases Network plans to undertake "research-based characterization" of patients with immunological disorders.
Mount Sinai Health Launches Center for Undiagnosed Diseases With $3.3M NIH Grant
precisionmedicineonline.com
-
Observation alone resulted in positive outcomes for MRD-negative patients, whereas MRD-positive individuals may still need adjuvant chemotherapy.
Natera Links ctDNA Status to Overall Survival, Therapy Response in GALAXY Study Update
precisionmedicineonline.com
-
The drug is approved in combination with an aromatase inhibitor as adjuvant therapy for breast cancer patients at high risk of recurrence.
FDA Approves Novartis' Kisqali as Adjuvant Treatment for Early-Stage HER2-Negative Breast Cancer
precisionmedicineonline.com
-
The test assigns a pancreatic cancer subtype based on the expression of 16 genes measured using an array.
UNC Pancreatic Cancer Test Aims to Classify Subtypes to Improve Therapy Selection
precisionmedicineonline.com
-
The Baltimore-based subsidiary of Japan's Sysmex said that the test is used to identify genetic mutations that are relevant for the treatment of various cancer types.
Sysmex Inostics Gets NYS CLEP Approval for Clinical Trial-Use Liquid Biopsy Assay
precisionmedicineonline.com
-
The firms will share data from the HERTHENA-Lung02 trial, in which patritumab deruxtecan improved patients' progression-free survival versus chemo.
Merck, Daiichi Sankyo to Discuss Antibody-Drug Conjugate Data in EFGR-Mutated NSCLC With Regulators
precisionmedicineonline.com
-
Janssen aims to enroll about 500 participants with presymptomatic Alzheimer's into the Phase IIb ReTain trial testing JNJ-2056.
Janssen Pharma to Make CHF 24.6M Milestone Payment to AC Immune Tied to Anti-Tau Alzheimer's Trial
precisionmedicineonline.com
-
NTLA-3001 uses CRISPR to insert a healthy copy of the SERPINA1 gene, which is perturbed in alpha-1 antitrypsin deficiency.
Intellia Therapeutics Testing Gene Insertion Therapy for AATD-Linked Lung Disease
